{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115424","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.279325+00:00","generated_at":"2026-06-22T05:26:38.086546+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Theravance Biopharma Q3 2022: YUPELRI sales up 35% YoY; $1.1B TRELEGY deal closed; debt-free","bullets":["Implied 35% share of YUPELRI net sales $18.7M, up 35% YoY; Viatris collaboration revenue $12.4M.","Closed TRELEGY royalty sale to Royalty Pharma for ~$1.1B upfront; gain of $1.14B; now debt-free with $486.8M cash.","Initiated $250M capital return; purchased GSK's 9.6M shares at $9.75/shr; Dutch tender up to $95M extended to Nov 17.","Operating expenses guidance: R&D $45-55M, SG&A $35-45M for FY2022 (excl. share-based comp and one-time costs).","Ampreloxetine Phase 3 study (CYPRESS) in MSA patients with nOH to start Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115424","json":"https://secwatch.observer/filing/0001104659-22-115424.json","markdown":"https://secwatch.observer/filing/0001104659-22-115424.md","text":"https://secwatch.observer/filing/0001104659-22-115424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465922115424/0001104659-22-115424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465922115424/tm2229828d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:26:38.086546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc184839d39eaac451059e47e928067152976af1","claim":"Theravance Biopharma, Inc. reported third quarter of 2022 results: revenue $12.5 million.","evidence_excerpt":"Revenue: Total revenue for the third quarter of 2022 was $12.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465922115424/0001104659-22-115424-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2022"},{"label":"Revenue","value":"$12.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}